Low molecular weight heparin and the risk of haemorrhage following percutaneous biopsy, despite a normal standard clotting screen.
There has been an increase of the use of low molecular weight heparin in the treatment of thrombotic events. This case report describes a complication of a pelvic mass biopsy performed whilst the patient was being treated with low molecular weight heparin (LMWH). Despite an uncomplicated biopsy procedure and confirmation of normal clotting screen, INR (International normalised ratio), APTR (Activated partial thromboplastin ratio) and platelet levels, the biopsy was complicated by severe haemorrhage.
Cook
C
C
Department of Clinical Radiology, Bristol Royal Infirmary, Marlborough Street, Bristol B52 8HW, UK.
Callaway
M
M
D000368:Aged; D001707:Biopsy, Needle / Q000009:adverse effects*; D018269:Carcinoma, Endometrioid / Q000097:blood / Q000473:pathology*; D017984:Enoxaparin / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006470:Hemorrhage / Q000097:blood / Q000139:chemically induced*; D006801:Humans; D007084:Iliac Vein; D019934:International Normalized Ratio; D008279:Magnetic Resonance Imaging; D009364:Neoplasm Recurrence, Local / Q000097:blood / Q000473:pathology*; D010051:Ovarian Neoplasms / Q000097:blood / Q000473:pathology*; D010053:Ovary / Q000473:pathology; D010314:Partial Thromboplastin Time; D012307:Risk Factors; D013927:Thrombosis / Q000097:blood / Q000188:drug therapy
D017984:Enoxaparin